Fabre-Kramer

Fabre-Kramer is a pharmaceutical company that specializes in the development of psychotropic drugs. Compounds in their current development pipeline include TGFK07AD and TGBA01AD for major depression, TGFK08AA and TGWOOAA for generalized anxiety disorder, and TGFK09SD for hypoactive sexual desire disorder.[1]

The company has also conducted clinical studies on a gepirone extended release formulation for major depression.[2][3][4]

References

  1. ↑ "Product Pipeline". Fabre Kramer Pharmaceuticals. Retrieved 2011-10-16.
  2. ↑ Fabre LF, Smith LC (August 2011). "The Effect of Major Depression on Sexual Function in Women". J Sex Med 9 (1): 231–9. doi:10.1111/j.1743-6109.2011.02445.x. PMID 21883948.
  3. ↑ Fabre LF, Smith LC, DeRogatis LR (September 2011). "Gepirone-ER treatment of low sexual desire associated with depression in women as measured by the DeRogatis Inventory of Sexual Function (DISF) fantasy/cognition (desire) domain--a post hoc analysis". J Sex Med 8 (9): 2569–81. doi:10.1111/j.1743-6109.2011.02330.x. PMID 21707926.
  4. ↑ Fabre LF, Brown CS, Smith LC, Derogatis LR (May 2011). "Gepirone-ER treatment of hypoactive sexual desire disorder (HSDD) associated with depression in women". J Sex Med 8 (5): 1411–9. doi:10.1111/j.1743-6109.2011.02216.x. PMID 21324094.

External links

This article is issued from Wikipedia - version of the Saturday, January 18, 2014. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.